Indo Us Bio-Tech Limited (NSE:INDOUS)
India · Delayed Price · Currency is INR 67.48
+0.93 (1.40%)
Nov 11, 2026, 2:19 PM IST
Indo Us Bio-Tech Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 10, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 1,360 | 1,963 | 2,953 | 4,451 | 2,131 | 619 | |
Market Cap Growth | -49.16% | -33.51% | -33.66% | 108.89% | 244.33% | 213.27% |
Enterprise Value | 1,669 | 2,234 | 3,094 | 4,565 | 2,258 | 729 |
Last Close Price | 66.55 | 98.21 | 148.96 | - | - | - |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 10, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 11.83 | 14.96 | 18.15 | 54.01 | 29.43 | 12.22 |
PS Ratio | 1.21 | 1.78 | 2.84 | 6.11 | 3.45 | 1.24 |
PB Ratio | 1.47 | 2.12 | 3.76 | 7.09 | 3.91 | 1.61 |
P/TBV Ratio | 1.47 | 2.12 | 3.76 | 7.09 | 3.91 | 1.61 |
P/FCF Ratio | - | - | 529.88 | - | - | - |
P/OCF Ratio | - | - | 208.03 | 200.36 | 405.26 | 22.89 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 10, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 1.48 | 2.02 | 2.98 | 6.27 | 3.66 | 1.46 |
EV/EBITDA Ratio | 10.73 | 13.11 | 16.24 | 41.25 | 24.03 | 10.50 |
EV/EBIT Ratio | 11.35 | 13.84 | 17.24 | 44.47 | 26.35 | 11.22 |
EV/FCF Ratio | - | - | 555.17 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 10, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.40 | 0.40 | 0.19 | 0.23 | 0.21 | 0.33 |
Debt / EBITDA Ratio | 2.38 | 2.17 | 0.78 | 1.29 | 1.23 | 1.85 |
Debt / FCF Ratio | - | - | 26.63 | - | - | - |
Net Debt / Equity Ratio | 0.33 | 0.33 | 0.19 | 0.21 | 0.21 | 0.33 |
Net Debt / EBITDA Ratio | 1.99 | 1.81 | 0.77 | 1.20 | 1.21 | 1.84 |
Net Debt / FCF Ratio | - | -2.06 | 26.18 | -34.02 | -8.80 | -10.12 |
Asset Turnover | - | 0.96 | 1.14 | 0.95 | 0.99 | 1.01 |
Inventory Turnover | - | 0.91 | 1.14 | 1.19 | 1.73 | 1.95 |
Quick Ratio | - | 0.50 | 0.93 | 1.07 | 2.04 | 1.68 |
Current Ratio | - | 3.05 | 5.31 | 3.88 | 4.87 | 3.81 |
Return on Equity (ROE) | - | 15.34% | 23.03% | 14.06% | 15.57% | 16.92% |
Return on Assets (ROA) | - | 8.74% | 12.31% | 8.34% | 8.57% | 8.18% |
Return on Invested Capital (ROIC) | 11.21% | 14.05% | 20.89% | 13.56% | 14.34% | 14.74% |
Return on Capital Employed (ROCE) | - | 17.20% | 22.00% | 15.70% | 15.00% | 15.00% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 10, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 8.45% | 6.69% | 5.51% | 1.85% | 3.40% | 8.18% |
FCF Yield | -11.02% | -7.64% | 0.19% | -0.09% | -0.61% | -2.04% |
Dividend Yield | - | - | 0.17% | - | - | 0.37% |
Payout Ratio | - | - | 3.08% | - | - | 3.00% |
Buyback Yield / Dilution | -0.34% | - | - | -3.95% | -57.60% | 15.96% |
Total Shareholder Return | -0.34% | - | 0.17% | -3.95% | -57.60% | 16.33% |